Vaccine Alliance, Gavi has entered into a $5m (£3.5m) deal for a worldwide Ebola vaccine - a development which will see 300,000 vaccines ready for emergency use or further clinical trials.
Pharmaceutical company, Merck is thus set to submit its application to license the vaccine by the end of 2017. Merck has led trials of the VSV-EBOV vaccine - which combines a fragment of the Ebola virus with another safer virus in order to train the immune system to combat the deadly Ebola epidermic.
Chief Executive of Gavi, Dr Seth Berkley has revealed to the media the need for a heightened intervention stating the epidermic remains a wake up call to the world.
The World Health Organisation (WHO) has declared West Africa completely free of the Ebola virus after Liberia documented an end of active transmission – thus going 42 days without any case in the country, joining Guinea which recently was declared safe.
The declaration which comes as good news to Liberians and the people of West Africa has thus seen the chief of the WHO, Margaret Chan assure of clinical means to ensure the virus is cleared from all survivors by the end of year.